- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03920813
Recruitment Status Enrolling by invitation
First Posted April 19, 2019
Last update posted April 23, 2019
The present study was conducted to assess the population pharmacokinetics of 6-mercaptopurine (6-MP) in Pediatric Acute Lymphoblastic Leukemia (ALL) and genetic polymorphisms
The investigators' purpose was to identify genetic factors and metabolite concentrations associated with both hematological toxicity in patients with ALL maintained on 6-MP in Chinese.
|Experimental: Antitumor drugs
Mercaptopurine administered at standard dose for children with hematological neoplasms.
Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- Patients have been diagnosed with Acute Lymphoblastic Leukemia
- Childhood patients who were undergoing chemotherapy or continuous follow-up after
completion of chemotherapy
- Patients received the phase of maintenance therapy that included oral 6-MP (>4 weeks)
and completion of ≥ 6 months according to the CCLG (Chinese Children's Leukemia Group)
- Patients with high-risk ALL (presence of higher-risk features: MRD ≥ 1% at 46 day, or
age < 6 month and white blood cell (WBC) count ≥ 300×109/L with translocations t(9;22) (q34;q11) [BCR-ABL], t(4;11) (q21;q23) [AF4/MLL], t(1;19) (q23;p13) [E2A-PBX1] or other MLL-rearrangements) were removed
Principal Investigator: Wei Zhao, Ph.D Shandong University